7.28 (-%)
As of Nov 01, 2024
Source:
We are a clinical-stage biopharmaceutical company pioneering a new class of complement medicines designed to stop the classical complement pathway at its start, C1q, in order to bring therapies to patients suffering from serious complement-mediated autoimmune, neurodegenerative and ophthalmic disorders. C1q, the initiating molecule of the classical complement pathway, is a core component to the body’s immune system that activates a powerful inflammatory cascade.
Country | United States |
Headquarters | brisbane, california |
Phone Number | (650)-822-5500 |
Industry | manufacturing |
CEO | Douglas Love, Esq. |
Website | www.annexonbio.com |